Spray-Drying Process Optimization and Modeling for an Inhaled Dry Powder of 5-Azacytidine for Treating Local and Metastatic Lung Cancer
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Rebekah M Anderson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bend Bioscience, Bend, Oregon 97701, United States. Hauptthemen laut MEDLINE: Lung Neoplasms, Azacitidine. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lovelace Biomedical.
Abstract (Originalsprache)
A spray-dried powder formulation of 5-azacytidine (5-AZA) recently showed significantly improved tumor reduction and systemic exposure for the potential treatment of metastatic lung cancer. To support clinical use, the target product profile required double the active loading. Here, a series of powders were spray dried to increase 5-AZA loading in the formulation, and process parameters were varied to identify variables controlling powder properties. Formulations were sprayed via in-line mixing, where separate dimethyl sulfoxide (DMSO) and aqueous solutions were mixed immediately upstream of atomization. A core-shell structure was observed matching previous reports of spray-dried l-leucine with sugar from water and ethanol. To the best of our knowledge, this is the first study investigating the process and structure of spray-dried l-leucine and trehalose using DMSO and water as processing solvents. Powders with glass transition temperatures (Tg) below room temperature were successfully manufactured with high yields, attributed to the crystalline l-leucine shell surrounding the low Tg core. The residual DMSO was controlled by the DMSO:water ratio and the composition of the core. Perturbed-Chain Statistical Associating Fluid Theory (PC-SAFT) was employed to understand droplet drying processes by developing ternary phase diagrams and drying trajectories. This work enables the manufacture of both dry inhalable 5-AZA powder for the treatment of lung cancer and low Tg materials previously thought to be unmanufacturable via spray drying. It also highlights the importance of aligning experimental data and theoretical models to improve our understanding of complex processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bend Bioscience, Bend, Oregon 97701, United States.
- Lovelace Biomedical Research Institute, Albuquerque, New Mexico 87108, United States.
- Amofor GmbH, Dortmund 44227, Germany.
ORCID-Profile: Rebekah M Anderson, Philip J Kuehl, Christian Luebbert, Michael E Grass
Förderung
- Lovelace Biomedical
Zitieren
APA
Anderson, R. M., Belinsky, S. A., Earnest, L. M., Kuehl, P. J., Luebbert, C., Ruzycki, C. A., Vodak, D. T., & Grass, M. E. (2025). Spray-Drying Process Optimization and Modeling for an Inhaled Dry Powder of 5-Azacytidine for Treating Local and Metastatic Lung Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00799
Vancouver
Anderson RM, Belinsky SA, Earnest LM, Kuehl PJ, Luebbert C, Ruzycki CA, et al. Spray-Drying Process Optimization and Modeling for an Inhaled Dry Powder of 5-Azacytidine for Treating Local and Metastatic Lung Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00799
BibTeX
@article{Anderson2025,
author = {Anderson, Rebekah M and Belinsky, Steven A and Earnest, Lindsey M and Kuehl, Philip J and Luebbert, Christian and Ruzycki, Conor A and Vodak, David T and Grass, Michael E},
title = {Spray-Drying Process Optimization and Modeling for an Inhaled Dry Powder of 5-Azacytidine for Treating Local and Metastatic Lung Cancer},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00799}
}
EUVIMED